Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC
To compare pharmacokinetics Index of Cipterbin combined with Vinorelbine Injection every week or every three weeks in the treatment of patients with HER2-positive metastatic breast cancer
Metastatic Breast Cancer
DRUG: Cipterbin Combined With Vinorelbine
Cmax, Cmax after the last administration, From enrollment to 21 days after the last dose administrate|Cmin, Cmin after the last administration, From enrollment to 21 days after the last dose administrate|AUC0-t, AUC0-t after the last administration, From enrollment to 21 days after the last dose administrate|AUCtau, AUCtau after the last administration, From enrollment to 21 days after the last dose administrate
Multiple sets of Cmax, Cmax after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group., From enrollment to 21 days after the last dose administrate|Multiple sets of Cmin, Cmin after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group., From enrollment to 21 days after the last dose administrate|Multiple sets of AUC0-t, AUC0-t after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group., From enrollment to 21 days after the last dose administrate|Multiple sets of AUCtau, AUCtau after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group., From enrollment to 21 days after the last dose administrate|Multiple sets of Tmax, Tmax after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group., From enrollment to 21 days after the last dose administrate|Safety index, Adverse Events during the test, From enrollment to 30 days after the last dose administrate|BOR, Record the proportion of CR and PR in all subjects, From enrollment to death(for any reason),Until 24 months after the last subject left the administration group|DCR, CR/PR/SD accounted for the proportion of all subjects, From enrollment to death(for any reason),Until 24 months after the last subject left the administration group|OS, Overall Survival of all subjects, From enrollment to death(for any reason),Until 24 months after the last subject left the administration group|Immunogenicity index, ADA, From enrollment to 21 days after the last dose administrate
A multi-center, randomized, open-label study on pharmacokinetics, safety, efficacy, and immunogenicity of Cipterbin combined with Vinorelbine Injection every week or every three weeks in the treatment of patients with HER2-positive metastatic breast cancer. The main purpose was to compare pharmacokinetics Index between two groups, secondly to observe safety, efficacy, and immunogenicity